SWK — Investor Presentation (May 2023)
32 slides from SWK's investor presentation, May 17, 2023
Slide 1: Collaborative Approach to Life Science Financing
1 Collaborative Approach to Life Science Financing Shareholder Presentation May 17, 2023
Slide 2: Forward-looking and Cautionary Statements
2 Forward - looking and Cautionary Statements Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we be lieve or anticipate will or may occur in the future are "forward - looking" statements within the meaning of the federal secu
Slide 3: SWK Holdings - Overview
SWK Holdings - Overview 3 Underserved, High - Need Market Demonstrated Success, Attractive Returns Focus on Shareholder Returns Custom financing solutions for commercial - stage healthcare companies and royalty owners • SWK targets $5mm to $25mm financings, a market niche that is largely ignored by
Slide 4: SWK Holdings - Segments
4 SWK Holdings - Segments LIFE SCIENCE SPECIALTY FINANCE ENTERIS BIOPHARMA • Senior secured term loans • Royalties • Synthetic royalties • Hybrid structures • CDMO and CMO services • Peptelligence ® and ProPerma Œ dosing technologies • 505b2 drug outlicensing SWK operates through two segments: Life
Slide 5: Why Mid-Market Life Science Finance?
5 Why Mid - Market Life Science Finance? Tap into underlying demand that is pervasive, growing, and minimally correlated with economic cycles • Healthcare spend large and increasing — represents ~20% of U.S. GDP, expected 5% CAGR through 2030 1 • Sector has demonstrated durability — S&P 500 sales -
Slide 6: Value Creation Strategy
6 Value Creation Strategy SWK believes this strategy will continue to achieve a 10%+ book value per share CAGR Deploy balance sheet capital into secured financing portfolio • SWK has established reputation as a go - to capital provider for this underserved market • Majority of financings structured
Slide 7: Book Value Components
7 Book Value Components Tangible Finance Book Value / Share = $18.45 • Excludes value of deferred tax asset, net Enteris intangibles and goodwill * , and Enteris PP&E • SWK's targets 10%+ CAGR of tangible finance book value / share • 1Q23 implementation of ASC 326 was a $12.2 million ($0.96 per shar
Slide 8: Corporate Milestones
8 Corporate Milestones 2016 x Team rebuilt and investment process improved x Focus on 1LTLs and Royalties only (no 2Ls, equity, high yield) x Ended year with $130.0mm investment assets 2017 x Holmdel sold – 3.5x CoC return x Ended year with $154.9mm investment assets 2018 x Secured $20mm credit faci
Slide 9: First Quarter 2023 Recap
First Quarter 2023 Recap 9 CONFIDENTIAL CORPORATE UPDATES FINANCE RECEIVABLES UPDATES • Michael Miner joined SWK as a Vice President on the underwriting team • Peter Blumberg joined as a Vice President on the business development team • Enteris has bid on approximately $7.0 million of CDMO projects
Slide 10: Finance Segment Portfolio Overview: 1Q23
10 Finance Segment Portfolio Overview: 1Q23 * Includes public company warrants; private warrants carried at zero value / not valued on balance sheet ** Includes only those assets with non - zero book value • Gross Finance Receivables: $248.8mm • Total Investment Assets: $249.6mm * Financing Segment
Slide 11: Financial Snapshot
11 Financial Snapshot * Eliminates provision for income taxes, Enteris intangibles amortization, and non - cash mark - to - market changes on warrant assets and equity securities; see reconciliation on page 30; 2019 Non - GAAP Adjusted Net Income was reduced by $1.2mm of Enteris transaction expenses
Slide 12: Financing Strategy: Effective Yields
0.0% 2.0% 4.0% 6.0% 8.0% 10.0% 12.0% 14.0% 16.0% $- $50.0 $100.0 $150.0 $200.0 $250.0 $300.0 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 Investments Assets and Weighted Effective Yield ($ in millions; at end of period) Total Investments Assets Portfolio Effective Yield * 12 Fina
Slide 13: Financing Strategy: Realized vs Effective Yield
13 Financing Strategy SWK's Portfolio Realized Yield Has Typically Exceeded the Projected Yield as Actual Receipts Exceeded Internal Forecasts *Portfolio Realized Yield is inclusive of all fees and is calculated based on the simple average of finance receivables at th e b eginning and end of period
Slide 14: Current Structured Credit Portfolio
Current Structured Credit Portfolio Advanced Oxygen Therapy 03.21.2022 $12.0 million Structured Credit Epica International 07.25.2018 $14.0 million Structured Credit MolecuLight 01.04.2022 $10.0 million Structured Credit BIOLASE 11.09.2018 $15.0 million Structured Credit Flowonix Medical 12.23.2020
Slide 15: Current Royalty Portfolio
15 Current Royalty Portfolio Best ABT 11.12.2018 $5.8 million Royalty Reorganization Coflex & Kybella 08.31.2020 $4.4 million Royalty Portfolio Acquisition Veru Healthcare 03.05.2018 $12.0 million Synthetic Royalty Financing Illuvien 12.18.2020 $16.5 million Royalty Acquisition ForFivo ( IntelGenx )
Slide 16: Portfolio Realizations: Exit History 2012-2022
16 Portfolio Realizations Exit History 2012 - 2022 Exited Deals 31 Exits Cash Deployed $377.0MM Cash Returned $528.8MM MOIC 1.40x IRR 17.8% ($s in MMs) Date Cash Investments # Security Invested Paid Off Invested Received MOIC IRR Nautilus 1 Loan Dec-12 Dec-13 22.5$ 28.6$ 1.3x 28% Parnell I 2 Loan Ja
Slide 17: Portfolio Realizations to Strategic Buyers
17 Portfolio Realizations to Strategic Buyers 13 realizations to strategic buyers demonstrated a median 28% LTV of SWK's original loan value 9 of the 13 businesses were not profitable at time of sale, validating SWK's revenue and IP - based underwriting methodology (1) Attachment point measured as f
Slide 18: Sourcing
18 Sourcing • SWK has a well - developed and diversified sourcing network • SWK balances proprietary opportunities with deal flow from trusted, boutique investment banks and brokers • SWK typically faces limited competition due to proprietary sourcing network and focus on sub - $25mm financings • Fr
Slide 19: Financing Structures
Financing Structures 19 Product Acquisition • Primarily first lien, senior secured, floating rate loans • Typically include covenants, prepayment penalties, origination and exit fees, and warrant coverage • Provide working capital to support product commercialization and M&A Hybrid Financing Synthet
Slide 20: Value Proposition to Partners
20 Value Proposition to Partners Smaller companies often don't have financial profile to qualify for traditional financing sources Companies in this niche often have few options outside of a dilutive equity raise The IPO market is largely closed to companies of this size requiring expensive and diff
Slide 21: Historical Financing: Narcan Royalty
Historical Financing: Narcan Royalty 21 OPPORTUNITY SOLUTION • Opiant is a publicly - traded drug development company that receives a royalty on Narcan for developing the drug's unique formulation • Novel formulation has a faster time to onset and more convenient and safer administration • Opiant ne
Slide 22: Historical Financing: Galil Medical
Historical Financing: Galil Medical 22 OPPORTUNITY SOLUTION • In 2014, Galil was on the cusp of accelerating revenue growth, but was not yet cash - flow positive and could not tap traditional financing channels • Galil needed additional capital to run clinical trials and expand its sales force • In
Slide 23: Enteris Corporate Overview
23 Enteris Corporate Overview CDMO Platform Revenue - Generating CDMO Platform and Proven Dosing Technology with Late - Stage Commercial Partnerships Drug Delivery Technology Internal 505(b)(2) Pipeline Company Highlights • Peptelligence and ProPerma allow for oral delivery of drugs that are typical
Slide 24: Enteris: Cara Therapeutics and Oral KORSUVA
Enteris: Cara Therapeutics and Oral KORSUVA Œ 24 Oral KORSUVA Licensing Agreement Milestone Payment • Formulated with Enteris' Peptelligence technology • Currently the subject of three late - stage clinical trials for pruritus: • Phase 3 trial targeting pruritus associated with non - dialysis depend
Slide 25: Leadership Team
25 Leadership Team Yvette Heinrichson Chief Financial Officer • Joined in 2016 • Technical GAAP accounting and SEC financial reporting • Certified Fraud Examiner • Served as financial statement auditor and tax professional with Deloitte for multiple years Jody Staggs President and Interim CEO • Join
Slide 26: Why Invest in SWKH - Attractive Risk Reward Scenario
Why Invest in SWKH – Attractive Risk Reward Scenario 26 Unleveraged Balance Sheet and Buyback • SWK story is not widely known, having uplisted to Nasdaq without benefit of traditional IPO • Analyst coverage and proactive investor relations effort have helped to increase SWK's visibility • With a Boo
Slide 27: Balance Sheet
27 Balance Sheet Certain asset and liabilities were classified as “current” in prior years; thus, prior periods may not be directly comparable . $ in 000s Mar-23 Dec-22 Dec-21 Dec-20 Dec-19 Dec-18 ASSETS Cash and cash equivalents 3,244$ 6,156$ 42,863$ 3,008$ 11,158$ 20,227$ Interest and accounts rec
Slide 28: Income Statement
28 Income Statement $ in 000s, except per share amounts LTM 1Q23 Dec-22 Dec-21 Dec-20 Dec-19 Dec-18 Revenues Finance receivable interest income, including fees 34,306$ 35,461$ 39,310$ 30,800$ 30,117$ 25,978$ Pharmaceutical development 5,367 5,485 16,122 5,903 621 - Other 91 538 723 9 9 12 Total reve
Slide 29: Reconciliation of Non-GAAP Adjusted Net Income
29 Reconciliation of Non - GAAP Adjusted Net Income The following tables provide a reconciliation of SWK's reported (GAAP) consolidated net income to SWK's adjusted consolidated ne t income (Non - GAAP) for the periods denoted in the table. The table eliminates provisions for income taxes, non - cas
Slide 30: Reconciliation of Non-GAAP Specialty Finance Net Income
30 Reconciliation of Non - GAAP Specialty Finance Net Income The following tables provide a reconciliation of SWK's consolidated adjusted income before provision for income taxes, listed in the table above, to the non - GAAP adjusted net income for the specialty finance business for the periods deno
Slide 31: Contact Information
31 Contact Information CONFIDENTIAL SWK Senior Management Investor & Media Relations: Tiberend Strategic Advisor • Jody Staggs: ̶ Phone: 972.687.7252 ̶ Email: [email protected] • Office address: ̶ 14755 Preston Road, Ste 105 Dallas, TX 75254 • Website: www.swkhold.com • Jason Rando: ̶ Email: jrand
Slide 32: Collaborative Approach to Life Science Financing
32 Collaborative Approach to Life Science Financing